Anti-HIV1 antibody (ab20460)
- Product nameAnti-HIV1 antibodySee all HIV1 primary antibodies ...
- DescriptionGoat polyclonal to HIV1
- SpecificityPurified virions, disrupted. Reacts with the whole virus. It reacts with all the major viral proteins including p17, p24, p53, p64, gp120, gp160, and gp41. We do not have any information about reactivity to reverse transcriptase, integrase, or protease. Does not react with T4+ human lymphocytes.
- Tested applicationsICC/IF, WB more details
Human isolate, confirmed.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPreservative: 0.1% Sodium Azide
Constituents: 0.01M PBS, pH 7.2.No stabilizing proteins have been added.
- Concentration information loading...
- PurityIgG fraction
- Purification notes>95% pure. Sodium sulfate precipitation and ion-exchange chromatography.
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab20460 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/50 - 1/100. The antibody was tested on HIV-1 strips. More concentrated antibody might be necessary for other sample formats for WB.|
- RelevanceHIV is a highly variable virus which mutates very readily. This means there are many different strains of HIV, even within the body of a single infected person. The strains of HIV1 can be classified into three groups : the "major" group M, the "outlier" group O and the "new" group N. These three groups may represent three separate introductions of simian immunodeficiency virus into humans. Group O appears to be restricted to West-Central Africa and group N, discovered in 1998 in Cameroon, is extremely rare. More than 90% of HIV1 infections belong to HIV1 group M.
- HIV 1 antibody
- HTLV3 antibody
- Human Immunodeficiency Virus 1 antibody
References for Anti-HIV1 antibody (ab20460)
ab20460 has not yet been referenced specifically in any publications.